Chemotherapy News and Research

Latest Chemotherapy News and Research

State highlights: Some hospitals aim for wealthier patients; N.C. Medicaid changes debated; Mich. panel Oks higher health care costs for workers

A selection of health policy stories from North Carolina, California, Michigan and Missouri.

17 Jan 2014

Different subtypes of HER2+ breast cancer facilitate more effective treatment tailored to specific tumor

Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.

17 Jan 2014

Facing Medicare funding cuts, Virginia hospitals push for Medicaid expansion

Expanding the program for low-income residents would help bring new revenue to the hospitals. Meanwhile, supporters of Medicaid expansion offer a new proposal in Nebraska and a young man in Utah diagnosed with cancer faces treatment problems because he lost his Medicaid coverage.

16 Jan 2014

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer.

16 Jan 2014

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

15 Jan 2014

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses.

15 Jan 2014

Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

The report Smoking and Health: Report of the Advisory Committee to the Surgeon General, identified tobacco as the predominant cause of lung cancer in men. This was the first widely disseminated report based on scientific studies showing the clear link between smoking tobacco and serious health conditions including cancer, chronic lung diseases and heart disease.

13 Jan 2014

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

10 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Montreal researchers identifies two specific key players in growth of GBM

Glioblastoma (GBM) is the most common and deadly form of primary malignant brain cancer accounting for approximately 15% of all brain tumours and occurring mostly in adults between the ages of 45 and 70.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Researchers at Case Western Reserve University have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer - a breakthrough that has the potential to improve outcomes for patients with the disease.

9 Jan 2014

Professor receives ALSF grant to develop cancer vaccine technology that help children to have healthy life

In 2004, a form of cancer known as neuroblastoma claimed the life of Alexandra (Alex) Scott, a little girl who gained national attention for using her lemonade stand to raise money for cancer research.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children.

7 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and deliver those drugs to separate parts of the cancer cell where they will be most effective. The technique was developed by researchers at North Carolina State University and the University of North Carolina at Chapel Hill.

7 Jan 2014

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Esophageal Squamous Cell Carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore (NUS) have discovered a biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells - cells from which malignant brain tumors are believed to originate and regenerate - and created an experimental vaccine to attack them.

6 Jan 2014

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Esophageal Squamous Cell Carcinoma, the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore have discovered a biomarker, called adenosine deaminase acting on RNA-1, which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

Chemotherapy News and Research

Latest Chemotherapy News and Research

State highlights: Some hospitals aim for wealthier patients; N.C. Medicaid changes debated; Mich. panel Oks higher health care costs for workers

Different subtypes of HER2+ breast cancer facilitate more effective treatment tailored to specific tumor

Facing Medicare funding cuts, Virginia hospitals push for Medicaid expansion

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

BMH-21 chemical compound has ability to shut down a common cancer process

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Montreal researchers identifies two specific key players in growth of GBM

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Professor receives ALSF grant to develop cancer vaccine technology that help children to have healthy life

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in